KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Current Liabilities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Total Current Liabilities for 6 consecutive years, with $75.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Total Current Liabilities fell 28.11% year-over-year to $75.4 million, compared with a TTM value of $75.4 million through Mar 2025, down 28.11%, and an annual FY2024 reading of $76.6 million, down 35.63% over the prior year.
  • Total Current Liabilities was $75.4 million for Q1 2025 at AbCellera Biologics, down from $76.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $221.1 million in Q2 2022 and bottomed at $49.5 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $106.9 million, with a median of $89.6 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 217.01% in 2022, then crashed 58.02% in 2023.
  • Year by year, Total Current Liabilities stood at $120.7 million in 2021, then decreased by 1.95% to $118.3 million in 2022, then grew by 0.59% to $119.0 million in 2023, then tumbled by 35.63% to $76.6 million in 2024, then fell by 1.59% to $75.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for ABCL at $75.4 million in Q1 2025, $76.6 million in Q4 2024, and $79.6 million in Q3 2024.